A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT03022045 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie